Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration
| Autor: | Paolo L. Morselli, JR Kilborn, Paul Turner, G Bianchetti, S J Warrington |
|---|---|
| Rok vydání: | 1980 |
| Předmět: |
Adult
Male Tachycardia Adrenergic beta-Antagonists Physical Exertion Administration Oral Biological Availability Hemodynamics Pharmacology Betaxolol Propanolamines Heart Rate Heart rate medicine Humans Pharmacology (medical) business.industry Respiration Antagonist Area under the curve Middle Aged Blood pressure Pharmacodynamics Anesthesia Injections Intravenous medicine.symptom business Research Article medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 10:449-452 |
| ISSN: | 0306-5251 |
| DOI: | 10.1111/j.1365-2125.1980.tb01787.x |
| Popis: | 1 In normal subjects, intravenous betaxolol given in doses which inhibited the tachycardia of exercise failed to affect the peak expiratory flow rate. 2 From 2 to 48 h after administration of 150 micrograms/kg in four normal subjects, there was no significant difference between the blood levels, whether given orally or intravenously. 3 At all times, heart rate and blood pressure, at rest and during exercise, were reduced equally after administration by both routes, but the area under the curve of exercise heart rate against time was significantly smaller (P < 0.05) after intravenous drug. 4 The absolute bioavailability of betaxolol was 89 +/- 5%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text